More than 250 million people worldwide live with chronic hepatitis B (HBV), yet there is still no accessible animal model for studying the disease or testing novel therapies. Researchers have now ...

It’s known that interferon-alpha (IFNα) activates interferon-stimulated genes (ISGs) and disrupts the hepatitis B virus (HBV) replication cycle. Pegylated (PEG)-IFNα has been widely used for its ...

Hepatitis B virus (HBV) reactivation is commonly observed in individuals with chronic HBV infection undergoing antineoplastic drug therapy. Paclitaxel (PTX) treatment has been identified as a ...

Hepatitis C and hepatitis B viruses both attack the liver, eventually causing deadly cirrhosis or cancer. But while antivirals can cure 95 percent of HCV infections, its cousin HBV has long eluded ...